8-K: Monopar Therapeutics Receives Ethics Clearance for Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr

Monopar Therapeutics has received ethics clearance in Australia to begin a Phase 1 trial of its radiopharmaceutical MNPR-101-Zr in patients with advanced cancers.

Summary

• Monopar Therapeutics has received Human Research Ethics Committee (HREC) clearance in Australia to commence a Phase 1 dosimetry trial of its novel radiopharmaceutical MNPR-101-Zr.
• The trial will enroll patients with advanced cancers and use positron emission tomography (PET) imaging to assess tumor uptake, normal organ biodistribution, and safety.
• MNPR-101-Zr is a zirconium-89 labeled version of MNPR-101, a proprietary antibody that targets the urokinase plasminogen activator receptor (uPAR).
• Preclinical studies showed high and selective uptake of MNPR-101-Zr in uPAR-expressing tumors, including triple-negative breast, colorectal, and pancreatic cancers.
• The company plans to evaluate the efficacy of a therapeutically radio-labeled version of MNPR-101, such as with actinium-225, if the Phase 1 trial results are encouraging.
• The Phase 1 trial is expected to enroll around 12 patients and is anticipated to initiate in the near future.

Sentiment

Score: 7

Explanation: The document is positive due to the HREC clearance and the start of a Phase 1 trial, but it also acknowledges the inherent risks in drug development. The management's comments are optimistic, and the preclinical data is encouraging.

Positives

• The HREC clearance is a significant milestone for Monopar, allowing them to proceed with their first human clinical trial of their uPAR targeting agent.
• Preclinical data suggests high and selective uptake of MNPR-101-Zr in tumors, indicating potential for targeted cancer treatment.
• The company is leveraging the growing interest in the radiopharma sector, which has seen impressive clinical data recently.
• The trial will provide crucial data on the safety and efficacy of MNPR-101-Zr in humans.

Negatives

• The trial is still in Phase 1, meaning there is no guarantee of success.
• There are risks associated with the research, development, regulatory approval, and commercialization of imaging agents and therapeutics.
• The HREC could potentially put the trial on clinical hold at any time.

Risks

• The Phase 1 clinical trial may not initiate or enroll patients in 2024.
• MNPR-101-Zr may cause unexpected serious adverse effects or fail to image cancer tumors in humans.
• The HREC could put the Phase 1 trial on clinical hold at any time.
• There are general risks and uncertainties surrounding the research, development, regulatory approval, and commercialization of imaging agents and therapeutics.

Future Outlook

Monopar plans to evaluate the efficacy of a therapeutically radio-labeled version of MNPR-101 bound to an isotope such as Ac-225 if the Phase 1 trial results are encouraging.

Management Comments

• This is a significant milestone for Monopar, said Chandler Robinson, MD, Monopars Chief Executive Officer.
• Following more than 18 months of extensive preclinical development, we believe we are well-positioned in this space.
• This is our first human clinical trial using our uPAR targeting agent.
• There has been quite impressive clinical data generated in the radiopharma sector of late, such as against PSMA and SSTR2 expressing cancers, and we believe this to be just the beginning.

Industry Context

The announcement aligns with the growing interest and clinical data in the radiopharmaceutical sector, particularly in targeted cancer therapies. The company is positioning itself to capitalize on the success of other radiopharmaceuticals targeting PSMA and SSTR2 expressing cancers.

Comparison to Industry Standards

• The development of MNPR-101-Zr is comparable to other radiopharmaceutical programs targeting specific receptors on cancer cells, such as PSMA for prostate cancer and SSTR2 for neuroendocrine tumors.
• Companies like Novartis with their Pluvicto (targeting PSMA) and Advanced Accelerator Applications with Lutathera (targeting SSTR2) have demonstrated the potential of targeted radiopharmaceuticals.
• Monopar's approach of targeting uPAR is novel and could address a different set of cancers, including triple-negative breast, colorectal, and pancreatic cancers, where there is a high unmet need.
• The Phase 1 trial will be crucial in determining if MNPR-101-Zr can achieve similar levels of tumor uptake and safety as other successful radiopharmaceuticals.

Stakeholder Impact

• Shareholders will likely view the HREC clearance positively, as it represents progress in the company's pipeline.
• The trial could potentially lead to new treatment options for cancer patients.
• Employees may be motivated by the advancement of the company's research.

Next Steps

• The company will initiate the Phase 1 dosimetry trial of MNPR-101-Zr in Australia.
• The trial will enroll approximately 12 patients with advanced cancers.
• The company will assess tumor uptake, biodistribution, and safety using PET imaging.
• If the Phase 1 results are encouraging, the company plans to evaluate the efficacy of a therapeutically radio-labeled version of MNPR-101.

Key Dates

Keywords

radiopharmaceutical, MNPR-101-Zr, cancer, clinical trial, Phase 1, uPAR, PET imaging, dosimetry, Monopar Therapeutics, HREC